Healthcare Journal of Oregon: Press Releases

Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism

CELEBRATION, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, announced the publication of “Long-term …

Fortrea Announces Date for Second Quarter 2025 Financial Results and Conference Call

DURHAM, N.C., July 16, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its second quarter 2025 financial results before the market opens on …

Amphista Therapeutics announces achievement of a research milestone in its collaboration with Merck triggering a milestone payment

Collaboration focuses on the discovery of novel, non-CRBN/VHL, Targeted Glue™ degraders for oncology and immunology indications Cambridge, UK, 16 July 2025 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery of next-generation, …

Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach

- New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant - - Voyager’s wholly-owned Alzheimer’s disease franchise now includes …

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that …

Global POISE Study Reaches Milestone of 600 Orthopedic Implants in Pediatric Patients, Advancing Research on the Safety and Efficacy of OrthoPediatrics® Products

WARSAW, Ind., July 16, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced a significant milestone in the ongoing …

Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis

-- Expanded funding builds on the initial agreement to accelerate development of Prime Editors for Cystic Fibrosis (CF) -- -- Prime Medicine to receive up to $24 million in additional funding from the Cystic Fibrosis Foundation -- -- Multiple hotspot Prime …

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025

Company Announcement Net sales of DARZALEX® in the second quarter of 2025 totaled USD 3,539 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; July 16, 2025 – …

La nouvelle science des superhumains : le système d’IA BioSport™ libère le potentiel caché des athlètes

CALGARY, Alberta et NEW YORK, 16 juill. 2025 (GLOBE NEWSWIRE) -- Dans une initiative qui marque le début d’une nouvelle ère dans le domaine de la sécurité et de la science de la performance des athlètes, The BioSport™ Health Inc, une société de technologie …

Neue Wissenschaft der Übermenschen: BioSport™ KI-System erschließt das verborgene Potenzial von Sportlern

CALGARY, Alberta, und NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- In einem Schritt, der eine neue Ära in der Sicherheit und Leistungswissenschaft von Sportlern einläutet, hat The BioSport™ Health Inc, ein Unternehmen für Präzisionsgesundheitstechnologie, …

Evox Therapeutics Expands Scientific Advisory Board

OXFORD, United Kingdom, July 16, 2025 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (“Evox” or the “Company”), a biotechnology company developing innovative therapies for rare, genetically driven neurodegenerative diseases using a next-generation gene editing …

علم Superhumans الجديد: نظام الذكاء الاصطناعي BioSport™ يكشف النقاب عن الإمكانات الرياضية الخفية

كالجاري، ألبرتا ونيويورك, July 16, 2025 (GLOBE NEWSWIRE) --  في خطوة تشير إلى عصر جديد في علم السلامة والأداء الرياضي، كشفت شركة BioSport™ Health Inc، المتخصصة في بتقنيات دقيقة للرعاية الصحية، اليوم عن هيئة استشارية عالمية تابعة لها - مجموعة متنوعة من نخبة …

Press Release: Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration

Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration Designation earned for a one-time intravitreal gene therapy designed to inhibit two key complement cascade pathways Geographic atrophy …

Communiqué de presse : Le SAR446597 de Sanofi a obtenu la désignation « fast track » aux États-Unis pour le traitement de l’atrophie géographique liée à la dégénérescence maculaire liée à l’âge

Le SAR446597 de Sanofi a obtenu la désignation « fast track » aux États-Unis pour le traitement de l’atrophie géographique liée à la dégénérescence maculaire liée à l’âge Cette désignation a été obtenue pour une thérapie génique intravitréenne à …

Jin Medical Launches Production at Plant No. 3, Accelerating Global Delivery from the Chuzhou Manufacturing Facility

Beijing, China, July 15, 2025 (GLOBE NEWSWIRE) -- Jin Medical International Ltd. (Nasdaq: ZJYL) (“Jin Medical”, and together with all its subsidiaries, the “Company”), a Nasdaq-listed provider of rehabilitation medical equipment, announced today that its …

Barrett Family Foundation Makes Historic Gift to Help Build Extraordinary in Healthcare

TORONTO, July 15, 2025 (GLOBE NEWSWIRE) -- In a defining moment for healthcare, the Barrett Family Foundation has made a transformative donation to St. Joseph’s Health Centre—part of Unity Health Toronto—to create the Barrett Centre for Quality Improvement …